DR. LUUK HILGERS PHD, CEO & CSO
Luuk Hilgers has more than 30 years of experience in vaccine research in established industry and bio-pharmaceutical start-ups. He pioneered synthetic molecules as immunomodulators and one molecule is exploited worldwide as adjuvant in single-shot vaccines for veterinary purposes . He co-founded LiteVax B.V. (previously CoVaccine B.V.) and co-developed CoVaccine HT and LiteVax Adjuvant for human therapeutic and prophylactic vaccines. He gained ample experience in turning innovative ideas into successful concepts and business and received several EU grants.